JP7173732B2 - 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用 - Google Patents

遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用 Download PDF

Info

Publication number
JP7173732B2
JP7173732B2 JP2017523290A JP2017523290A JP7173732B2 JP 7173732 B2 JP7173732 B2 JP 7173732B2 JP 2017523290 A JP2017523290 A JP 2017523290A JP 2017523290 A JP2017523290 A JP 2017523290A JP 7173732 B2 JP7173732 B2 JP 7173732B2
Authority
JP
Japan
Prior art keywords
trypanosoma cruzi
polypeptide
sample
antibodies
cruzi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017523290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533913A (ja
JP2017533913A5 (enExample
Inventor
ウプマイヤー，バーバラ
ツァルント，トラルフ
レスラー，ディーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP14192004.1A external-priority patent/EP3018479A1/en
Priority claimed from EP15161274.4A external-priority patent/EP3072902A1/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2017533913A publication Critical patent/JP2017533913A/ja
Publication of JP2017533913A5 publication Critical patent/JP2017533913A5/ja
Priority to JP2021042064A priority Critical patent/JP7356467B2/ja
Application granted granted Critical
Publication of JP7173732B2 publication Critical patent/JP7173732B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017523290A 2014-11-06 2015-11-04 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用 Active JP7173732B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021042064A JP7356467B2 (ja) 2014-11-06 2021-03-16 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14192004.1 2014-11-06
EP14192004.1A EP3018479A1 (en) 2014-11-06 2014-11-06 Antigen composition for detecting Chagas disease
EP15161274.4A EP3072902A1 (en) 2015-03-27 2015-03-27 Recombinant Trypanosoma cruzi JL7 antigen variants and their use for detecting Chagas disease
EP15161274.4 2015-03-27
PCT/EP2015/075692 WO2016071393A1 (en) 2014-11-06 2015-11-04 Recombinant trypanosoma cruzi jl7 antigen variants and their use for detecting chagas disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021042064A Division JP7356467B2 (ja) 2014-11-06 2021-03-16 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用

Publications (3)

Publication Number Publication Date
JP2017533913A JP2017533913A (ja) 2017-11-16
JP2017533913A5 JP2017533913A5 (enExample) 2018-06-28
JP7173732B2 true JP7173732B2 (ja) 2022-11-16

Family

ID=54478742

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017523290A Active JP7173732B2 (ja) 2014-11-06 2015-11-04 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用
JP2021042064A Active JP7356467B2 (ja) 2014-11-06 2021-03-16 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021042064A Active JP7356467B2 (ja) 2014-11-06 2021-03-16 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用

Country Status (6)

Country Link
US (1) US10228370B2 (enExample)
EP (1) EP3215849B1 (enExample)
JP (2) JP7173732B2 (enExample)
CN (1) CN107074921B (enExample)
MX (1) MX2017005644A (enExample)
WO (1) WO2016071393A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4481385A4 (en) * 2022-03-25 2025-06-04 Sekisui Medical Co., Ltd. Immunoassay reagent and immunoassay method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508506A (ja) 1997-12-18 2002-03-19 コリクサ コーポレイション Ｔ．ｃｒｕｚｉ感染の検出および予防のための化合物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976763B1 (en) 1998-07-30 2003-11-05 Innogenetics N.V. Antigens and immunoassays for diagnosing Chagas' disease
PE20050942A1 (es) 2003-12-04 2005-11-10 Louis V Kirchhoff Polipeptidos recombinantes para diagnosticar la infeccion con el trypanosoma cruzi
EP2182979A4 (en) 2007-07-30 2010-09-08 Univ Georgia DIAGNOSTIC TEST OF TRYPANOSOMA CRUZI INFECTION
US20090325204A1 (en) * 2008-06-27 2009-12-31 Reed Steven G Compounds and methods for diagnosis and treatment of chagas disease
WO2010142829A1 (es) 2009-06-12 2010-12-16 Consejo Superior De Investigaciones Científicas (Csic) Método de obtención de datos útiles para el diagnóstico diferencial de la enfermedad de chagas, y para evaluar la respuesta al tratamiento
FR2952649B1 (fr) * 2009-11-13 2012-05-04 Univ Victor Segalen Bordeaux 2 Applications therapeutiques et diagnostiques contre les trypanosomoses animales africaines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508506A (ja) 1997-12-18 2002-03-19 コリクサ コーポレイション Ｔ．ｃｒｕｚｉ感染の検出および予防のための化合物および方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｃｌｉｎ．Ｖａｃｃｉｎｅ Ｉｍｍｕｎｏｌ．，２００９，Ｖｏｌ．１６，Ｎｏ．６，ｐｐ．８９９－９０５
Ｅｘｐ．Ｐａｒａｓｉｔｏｌ．，２０１１，Ｖｏｌ．１２７，ｐｐ．６７２－６７９
Ｊ．Ｉｍｍｕｎｏｌ．Ｍｅｔｈｏｄｓ，２００１，Ｖｏｌ．２５７，ｐｐ．５１－５４
Ｔｒａｎｓｆｕｓｉｏｎ，２００３，Ｖｏｌ．４３，ｐｐ．９１－９７

Also Published As

Publication number Publication date
US10228370B2 (en) 2019-03-12
JP2017533913A (ja) 2017-11-16
MX2017005644A (es) 2017-06-29
CN107074921B (zh) 2021-03-16
US20170248598A1 (en) 2017-08-31
JP2021098746A (ja) 2021-07-01
EP3215849A1 (en) 2017-09-13
BR112017007592A2 (pt) 2018-02-27
CN107074921A (zh) 2017-08-18
JP7356467B2 (ja) 2023-10-04
EP3215849B1 (en) 2018-12-19
WO2016071393A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
CN108650889B (zh) 用于诊断病毒感染的免疫测定法
EP2488872B1 (en) Methods for prrsv detection
US10094828B2 (en) Antigen composition for detecting Chagas disease
JP7356467B2 (ja) 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用
KR102898132B1 (ko) Hcv 항원의 다중-에피토프 융합 단백질 및 이의 용도
JP4166940B2 (ja) Ｈｉｖウイルスに対して免疫反応性である抗体の検出用の合成抗原
EP3072902A1 (en) Recombinant Trypanosoma cruzi JL7 antigen variants and their use for detecting Chagas disease
HK1236542B (zh) 重组克氏锥虫jl7抗原变体及其用於检测查加斯病的用途
HK1236542A1 (en) Recombinant trypanosoma cruzi jl7 antigen variants and their use for detecting chagas disease
BR122024013996A2 (pt) Composição de polipeptídeos, métodos de produção de polipeptídeo jl7 e de detecção de anticorpos, uso de uma composição de polipeptídeos e kit de reagentes
BR112017007592B1 (pt) Composição de polipeptídeo, métodos de produção de polipeptídeo jl7 e de detecção de anticorpos, uso de uma composição de polipeptídeos e kit de reagentes
JP2015028479A (ja) 抗トレポネーマ属（Ｔｒｅｐｏｎｅｍａ）抗体の検出のためのＴｐＮ１７に基づくイムノアッセイにおける、抗干渉添加剤としてのコレラ菌（Ｖｉｂｒｉｏｃｈｏｌｅｒａｅ）リポタンパク質１５（Ｌｐ１５）変異体
US20250258182A1 (en) Rocky mountain spotted fever detection and treatment
HK1238335B (zh) 用於检测查加斯病的抗原组合物
HK1238335A1 (en) Antigen composition for detecting chagas disease
CN112180096A (zh) 用于诊断线虫感染的新测定法
BR122024013968A2 (pt) Composição de polipeptídeos, método para produzir uma composição, métodos para detectar anticorpos, uso de uma composição e kit
BR122024013968B1 (pt) Composição de polipeptídeos, método para produzir uma composição, métodos para detectar anticorpos, uso de uma composição e kit
BR112017006569B1 (pt) Composição de polipeptídeos, método para produzir uma composição, métodos para detectar anticorpos, uso de uma composição e kit
KR19980074160A (ko) HIV-1 항원 p24 및 gp41의 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201118

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210316

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211119

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220203

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220914

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221007

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221007

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221104

R150 Certificate of patent or registration of utility model

Ref document number: 7173732

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150